<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797132</url>
  </required_header>
  <id_info>
    <org_study_id>VX15-809-115</org_study_id>
    <secondary_id>2016-001004-33</secondary_id>
    <nct_id>NCT02797132</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del</brief_title>
  <official_title>A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study evaluating the
      pharmacokinetics (PK), safety, tolerability, and pharmacodynamics (PD) of multiple doses of
      Lumacaftor/Ivacaftor (LUM/IVA) in subjects 2 through 5 years of age (inclusive) with Cystic
      Fibrosis (CF), homozygous for F508del. Subjects who participate in Part A may participate in
      Part B, if patient meet the eligibility criteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic (PK) parameters of lumacaftor (LUM) and ivacaftor (IVA): estimated peak concentrations (Cmax)</measure>
    <time_frame>up to 15 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic (PK) parameters of lumacaftor (LUM) and ivacaftor (IVA): estimated trough concentrations (Ctrough)</measure>
    <time_frame>up to 15 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline up to 28 days after last dose (up to 28 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: PK parameters of LUM and IVA metabolites: estimated peak concentrations (Cmax) of lumacaftor and ivacaftor metabolites</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: PK parameters of LUM and IVA metabolites: estimated trough concentrations (Ctrough) of lumacaftor and ivacaftor metabolites</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline up to 10 +/- 3 days after the last dose (up to 25 +/- 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change from baseline in sweat chloride level</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change from baseline in body mass index (BMI) and BMI for age z score</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change from baseline in weight and weight for age z score</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change from baseline in stature and stature for age z score</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change from baseline in lung clearance index (LCI)2.5</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change from baseline in LCI5.0</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Time-to-first pulmonary exacerbation</measure>
    <time_frame>through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of pulmonary exacerbations</measure>
    <time_frame>through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of CF-related hospitalizations</measure>
    <time_frame>through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B; Absolute change from Baseline in fecal elastase-1 (FE-1) levels</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change in serum levels of immunoreactive trypsinogen (IRT)</measure>
    <time_frame>from baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Changes in sputum microbiology cultures</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV1)</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Acceptability/palatability of LUM/IVA granules measured using hedonic scale</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: PK parameters of LUM, IVA, and their respective metabolites: estimated trough concentrations (Ctrough) of LUM and IVA and their metabolites</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part A: LUM/IVA Subjects &lt; 14Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lumacaftor 100 mg/ivacaftor 125 mg q12h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LUM/IVA Subjects &gt;= 14Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lumacaftor 150 mg/ivacaftor 188 mg q12h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LUM/IVA Subjects &lt; 14Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lumacaftor 100 mg/ivacaftor 125 mg q12h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LUM/IVA Subjects &gt;= 14Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lumacaftor 150 mg/ivacaftor 188 mg q12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lumacaftor/ ivacaftor</intervention_name>
    <arm_group_label>Part A: LUM/IVA Subjects &lt; 14Kg</arm_group_label>
    <arm_group_label>Part A: LUM/IVA Subjects &gt;= 14Kg</arm_group_label>
    <arm_group_label>Part B: LUM/IVA Subjects &lt; 14Kg</arm_group_label>
    <arm_group_label>Part B: LUM/IVA Subjects &gt;= 14Kg</arm_group_label>
    <other_name>Orkambi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who weigh ≥8 kilogram (kg) without shoes and wearing light clothing at the
             Screening Visit

          -  Subjects with confirmed diagnosis of CF at the Screening Visit

          -  Subjects who are homozygous for the F508del Cystic fibrosis transmembrane conductance
             regulator (CFTR) mutation

        Exclusion Criteria:

          -  Any clinically significant laboratory abnormalities at the Screening Visit that would
             interfere with the study assessments or pose an undue risk for the subject

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 28 days before Day 1

          -  A standard 12 lead ECG demonstrating QTc &gt;450 millisecond (msec) at the Screening
             Visit.

          -  History of solid organ or hematological transplantation.

          -  Ongoing or prior participation in an investigational drug study (including studies
             investigating LUM and/or IVA) within 30 days of the Screening Visit.

          -  History of cataract/lens opacity or evidence of cataract/lens opacity determined to be
             clinically significant by a licensed ophthalmologist during the ophthalmologic
             examination at the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

